Biodexa Pharmaceticals Cash Flow Conversion Efficiency
Biodexa Pharmaceticals cash flow conversion efficiency. Based on the latest financial reports, Biodexa Pharmaceticals (BDRX) has a cash flow conversion efficiency ratio of -0.204x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.33 Million) by net assets ($11.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Biodexa Pharmaceticals (2012–2025)
Cash flow conversion efficiency of Biodexa Pharmaceticals from 2012 to 2025. This chart illustrates how Biodexa Pharmaceticals's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BDRX stock price for real-time trading data and today's change.
Biodexa Pharmaceticals Cash Flow Conversion Ratio Explained
Biodexa Pharmaceticals cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biodexa Pharmaceticals Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biodexa Pharmaceticals ranked by their cash flow conversion efficiency. Also see Biodexa Pharmaceticals market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alexium International Group Limited
F:E7T
|
-0.087x |
|
Dios Exploration Inc.
V:DOS
|
-0.019x |
|
Monarca Minerals Inc
V:MMN
|
0.008x |
|
Middlefield Canadian Income PCC - Middlefield Canadian Income - GBP PC
LSE:MCT
|
0.005x |
|
Sodas Sodyum Sanayi AS
IS:SODSN
|
0.362x |
|
MW Trade S.A.
WAR:MWT
|
-0.050x |
|
Hedera Group publ AB
ST:HEGR
|
0.021x |
|
SEKUR PRIVATE DATA LTD.
F:GDT0
|
-0.388x |
Annual Cash Flow Conversion Efficiency for Biodexa Pharmaceticals (2012–2025)
The table below shows the annual cash flow conversion efficiency of Biodexa Pharmaceticals from 2012 to 2025. Review how financially flexible is Biodexa Pharmaceticals to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $11.38 Million | $-5.39 Million | -0.474x | +67.84% |
| 2024-12-31 | $8.32 Million | $-12.26 Million | -1.473x | -0.97% |
| 2023-12-31 | $4.68 Million | $-6.83 Million | -1.459x | +34.54% |
| 2022-12-31 | $3.16 Million | $-7.05 Million | -2.229x | -287.79% |
| 2021-12-31 | $10.45 Million | $-6.01 Million | -0.575x | +58.48% |
| 2020-12-31 | $6.72 Million | $-9.30 Million | -1.384x | -317.29% |
| 2019-12-31 | $19.56 Million | $-6.49 Million | -0.332x | +58.25% |
| 2018-12-31 | $16.92 Million | $-13.45 Million | -0.795x | -112.75% |
| 2017-12-31 | $34.68 Million | $-12.95 Million | -0.374x | -30.52% |
| 2016-12-31 | $45.72 Million | $-13.09 Million | -0.286x | -8.03% |
| 2015-12-31 | $46.89 Million | $-12.42 Million | -0.265x | -103.91% |
| 2014-12-31 | $41.99 Million | $-5.46 Million | -0.130x | +97.77% |
| 2013-12-31 | $760.00K | $-4.44 Million | -5.837x | -1601.94% |
| 2012-12-31 | $-8.28 Million | $-3.22 Million | 0.389x | -- |
About Biodexa Pharmaceticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment … Read more